abstract KEYWORD INDEX psoriatic arthritis 20, 128, 215, 514, 515, 521, 523, 528, 530, 531, 532, 536, 538, 541, 543, 546, 554, 664, 758, 761, 783, 793, 833, 849, 856, 1105, 1372, 1618, 1621, 1634, 1667, 1799, 1919, 1920, 1926, 1928, 1930, 1932, 1935, 1936, 1937, 1939, 1940, 1943, 1950, 1951, 1952, 1954, 1955, 1956, 1960, 1962, 1966, 1968, 1971, 1974, 1975, 1976, 1979, 1983, 1984, 2130, 2182, 2183, 2273 psychological status 449, 802, 1024, 1343, 1862 psychosocial factors 449, 683, 1320, 1321, 1324, 1347, 1348, 1428, 1645, 1748, 2064 PTPN2 1607 PTPN22 824, 1076 public health 974 public relation 2081 pulmonary arterial hypertension 564, 565, 568, 618, 1157, 1210, 1223 pulmonary complications 83, 561, 568, 569, 570, 585, 586, 587, 599, 602, 618, 619, 727, 829, 916, 923, 931, 1004, 1042, 1044, 1157, 1166, 1218, 1227, 1231, 1395, 1669, 1720 pulmonary embolism 1285 pulmonary fibrosis 604 pulmonary hypertension 567, 569, 570, 585, 586, 592, 595, 598, 727, 1004 pulmonary interstitial fibrosis 1635 pulmonary rheumatoid nodules 1810 purine nucleoside phosphorylase inhibition 150 purpura 2013 Q qualitative 1332 qualitative research 1321 quality appraisal 755 quality improvement 221, 993 quality indicators 2113 quality measurement 993 quality <strong>of</strong> care 59, 70, 72, 87, 162, 484, 789, 985, 986, 989, 991, 993, 995, 998, 999, 1002, 1007, 1010, 1011, 1056, 1332, 1334, 1338, 1428, 1571, 1735, 1856, 1923, 2112, 2113, 2279 quality <strong>of</strong> life 99, 116, 146, 155, 172, 207, 296, 572, 595, 625, 628, 688, 759, 769, 772, 795, 817, 818, 967, 975, 1063, 1096, 1165, 1204, 1325, 1326, 1337, 1340, 1346, 1347, 1423, 1425, 1572, 1645, 1685, 1747, 1748, 1767, 1777, 1787, 1836, 1848, 1872, 1920, 1928, 2070, 2072, 2073, 2090, 2195, 2207, 2281 quantiferon 997 quantitative imaging marker 135 questionnaires 44, 207, 225, 522, 625, 813, 1001, 1009, 1013, 1339, 1348, 1405, 1563, 1752, 1767, 1778, 1920, 1923, 2057, 2072, 2073, 2093, 2110, 2279 QuickDASH 1749 quinolone 2212 R RA prediction model 133 rabbit 1111 race/ethnicity 501, 589, 1140, 1330, 1556, 1557, 1565, 1592, 1875, 2095, 2145 radai 1750 radial tunnel syndrome 2223 radiographic joint damage 1580 radiographic outcomes 1496 radiographic progression 669, 1120 radiography 121, 124, 139, 140, 143, 181, 182, 185, 187, 303, 311, 665, 668, 728, 952, 1368, 1393, 1611, 1771, 1950, 1953, 1954, 1962, 1985, 2257 radioisotope bone scan 1665 radiological progression 290 Raf kinase inhibitor protein 366 RAGE 632 RAID 1750 RAMRIS 118, 125, 1369 randomized trials 574, 646, 664, 676, 690, 1102, 1113, 1129, 1319, 1325, 1368, 1545, 1559, 1560, 1791, 1808, 1839, 2280 RANK/RANKL pathway 30, 394, 842, 1269, 1482, 1488, 1492, 1497 ranking 687 rapamycin 1185, 1196 RAPID3 1120 rare variants 2144 RA-related autoimmunity 77 Ras GTPase 1529 rats 1480 raw 246.7 1492 Raynaud’s phenomenon 574, 579, 593, 608, 1201, 1215, 2086 reactivation 329 reactive arthritis 552, 696, 761, 1647 reactive oxygen species 631 real life 315 recombinant domain I 1358 recruitment 1559, 2083 recurrent idiopathic pericarditis 837 red blood cells 2277 regeneration 1479 register study 761 registry 400, 454, 569, 975, 17901792, 1802, 2064 regulatory cells 292, 737, 1125, 1242, 1248, 1256, 1257, 1261, 1265, 1267, 1268, 1374, 1827, 1903, 1977, 2236 regulatory natural antibodies 2121 regulatory T cell 442, 738, 909, 2128, 2131 rehabilitation 1321, 1342, 1458, 2050, 2060 relative risk 1036 reliability 140, 1316, 1616, 1623, 1629, 1749, 1954 remission 73, 138, 141, 232, 251, 308, 315, 317, 320, 331, 337, 343, 347, 480, 655, 662, 723, 766, 1050, 1051, 1103, 1278, 1396, 1631, 1701, 1737, 1754, 1758, 1793, 1800, 1823, 1829, 2108 renal 147, 1453 renal biopsy 1399 renal disease 164, 441, 443, 556, 643, 725, 1173, 1190, 1195, 1399, 1415, 1592 renal failure 1662 renal function 161, 1023 replication 329 reporters 1733 repulsion factors 361 resistance training 1384 responder definition 94 response 175 response criteria 1809, 1922 responsiveness 140, 772, 2207 resveratrol 1530 retinal vascular caliber 1772 retreatment 1905 retroperitoneal fibrosis 705, 1662 revision risk 2137 rheumatic diseases 962, 1026 rheumatoid arthritis (RA) 16, 17, 21, 22, 27, 33, 39, 41, 42, 46, 49, 50, 52, 53, 56, 57, 58, 59, 60, 61, 63, 64, 66, 67, 68, 69, 70, 72, 73, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 90, 101, 112, 118, 119, 125, 129, 132, 133, 135, 136, 138, 139, 141, 168, 274, 279, 282, 288, 290, 295, 296, 297, 300, 301, 302, 303, 306, 308, 309, 310, 313, 314, 315, 316, 317, 320, 321, 323, 324, 326, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 343, 344, 345, 346, 347, 348, 350, 351, 356, 357, 362, 363, 365, 368, 374, 375, 378, 383, 389, 390, 391, 393, 394, 397, 398, 401, 402, 403, 406, 409, 413, 414, 416, 419, 421, 523, 539, 636, 638, 639, 640, 643, 645, 658, 659, 660, 661, 697, 698, 717, 723, 735, 739, 743, 745, 755, 756, 759, 762, 770, 775, 778, 781, 785, 787, 794, 827, 847, 848, 849, 853, 856, 858, 861, 871, 880, 968, 970, 981, 983, 984, 987, 991, 993, 995, 1009, 1013, 1014, 1015, 1016, 1017, 1018, 1019, 1020, 1021, 1022, 1023, 1024, 1025, 1026, 1027, 1028, 1030, 1034, 1035, 1037, 1038, 1039, 1040, 1041, 1042, 1043, 1044, 1045, 1047, 1048, 1049, 1050, 1052, 1053, 1056, 1057, 1058, 1060, 1062, 1063, 1064, 1065, 1066, 1067, 1068, 1070, 1072, 1073, 1074, 1075, 1077, 1079, 1081, 1083, 1086, 1087, 1089, 1091, 1094, 1096, 1101, 1102, 1103, 1104, 1106, 1109, 1110, 1113, 1117, 1124, 1125, 1128, 1131, 1133, 1136, 1138, 1223, 1255, 1263, 1269, 1271, 1324, 1325, 1332, 1333, 1369, 1370, 1386, 1392, 1395, 1411, 1421, 1432, 1442, 1443, 1496, 1504, 1517, 1518, 1520, 1524, 1527, 1528, 1534, 1545, 1550, 1559, 1570, 1571, 1580, 1581, 1582, 1588, 1589, 1593, 1596, 1597, 1598, 370 2010 Program Book
1599, 1600, 1603, 1605, 1606, 1609, 1610, 1611, 1618, 1621, 1629, 1632, 1634, 1636, 1641, 1648, 1708, 1712, 1721, 1722, 1724, 1731, 1735, 1736, 1738, 1739, 1741, 1742, 1743, 1744, 1745, 1747, 1748, 1749, 1750, 1751, 1752, 1753, 1754, 1757, 1758, 1759, 1760, 1761, 1762, 1763, 1765, 1767, 1768, 1769, 1770, 1772, 1773, 1774, 1775, 1776, 1777, 1778, 1779, 1780, 1781, 1782, 1783, 1784, 1785, 1786, 1787, 1788, 1789, 1790, 1793, 1794, 1795, 1797, 1798, 1803, 1809, 1811, 1815, 1817, 1823, 1824, 1825, 1826, 1834, 1835, 2063, 2064, 2065, 2066, 2081, 2108, 2114, 2115, 2118, 2119, 2127, 2135, 2142, 2162, 2163, 2165, 2166, 2167, 2168, 2169, 2172, 2173, 2182, 2207, 2210, 2211, 2215, 2216, 2217, 2218, 2221, 2222, 2245, 2256, 2257, 2258, 2259, 2260, 2261, 2267, 2279, 2280, 2283, 2284 rheumatoid arthritis synovial tissue 371 rheumatoid arthritis, animal models 269, 270, 271, 272, 276, 278, 280, 281, 284, 285, 286, 289, 292, 635, 713, 714, 716, 855, 896, 1130, 1137, 1256, 1266, 1351, 1417, 1420, 1495, 1613, 1622, 1708, 1709, 1712, 1714, 1715, 1717, 1719, 1720, 1723, 1725, 1726, 1727, 1728, 1731, 1733, 2128, 2227, 2232, 2234, 2236, 2237 rheumatoid arthritis, disease activity measurement 1003 rheumatoid arthritis, pathogenesis 25, 30, 245, 250, 255, 349, 352, 354, 356, 359, 361, 364, 366, 370, 371, 372, 1071, 1076, 1078, 1080, 1082, 1085, 1088, 1090, 1092, 1093, 1247, 1252, 1254, 1353, 1390, 1391, 1417, 1505, 1506, 1786, 1801, 1968, 2116, 2130 rheumatoid arthritis, synovium 23, 29, 36, 291, 353, 355, 360, 364, 367, 623, 1051, 1069, 1240, 1387, 1416, 1508, 1515, 1527, 1529, 1535, 1604, 1822 rheumatoid arthritis, treatment 51, 54, 55, 62, 75, 76, 120, 123, 273, 278, 280, 281, 284, 298, 311, 312, 318, 319, 322, 324, 328, 330, 339, 341, 342, 344, 357, 376, 377, 380, 381, 392, 396, 400, 405, 407, 408, 410, 411, 412, 417, 418, 420, 641, 642, 662, 663, 744, 791, 1003, 1010, 1013, 1032, 1036, 1046, 1054, 1055, 1084, 1095, 1097, 1098, 1099, 1100, 1105, 1108, 1111, 1112, 1114, 1115, 1116, 1118, 1119, 1120, 1121, 1122, 1123, 1127, 1129, 1132, 1134, 1135, 1137, 1387, 1393, 1394, 1396, 1397, 1440, 1444, 1445, 1467, 1507, 1542, 1715, 1718, 1730, 1766, 1771, 1791, 1792, 1796, 1799, 1802, 1805, 1806, 1807, 1808, 1810, 1814, 1816, 1819, 1820, 1821, 1827, 1828, 1829, 1830, 1832, 1833, 1838, 1840, 1841, 2164, 2170, 2171, 2204, 2233, 2262, 2263, 2264, 2265, 2282 rheumatoid factor (RF) 660 rheumatoid factor negative 1830 rheumatoid factor positive 1830 rheumatoid nodule 1060 rheumatoid vasculitis 1020 rheumatologic practice 41, 48, 310, 995, 1003, 1024, 1338, 1560, 2109 rheumatology fellows 1429 rheumatology practice 109 rheumatology practice audit 1735 ribonucleoprotein (RNP) 608, 852, 1267, 2175 right heart pressures 567 risedronate 2156 risk 1956 risk assessment 5, 521, 554, 562, 589, 793, 919, 972, 997, 1026, 1039, 1048, 1053, 1082, 1233, 1285, 1551, 1554, 1576, 1588, 1842, 1849, 1914, 2153, 2212 risk factors 774, 976, 1877, 1936, 2100 Ritchie articular index 295 rituximab 55, 321, 332, 333, 340, 375, 391, 401, 403, 405, 406, 409, 465, 678, 680, 700, 738, 739, 740, 744, 767, 917, 1084, 1098, 1118, 1144, 1153, 1295, 1379, 1582, 1671, 1693, 1790, 1801, 1807, 1810, 1821, 1828, 1830, 1833, 1889, 1892, 1893, 1894, 1905, 1955, 2041, 2042, 2201, 2263 RNA- and DNA-based agonists 862 RNA binding protein 487 RNA polymerase III antibody 1231 RNA-binding protein 934 RNAi therapeutics 2174 Ro/SSA 2175 Ro60 1901 ROC curves 1775 RORgamma t 1260 ROS 657 rural health care 2050 S S100 proteins 845, 1472 S100A4 614 S100A8 1495, 2002 sacroiliac joints 1962 sacroiliitis 527, 665, 1279 safety 97, 147, 163, 177, 390, 1172, 1454, 1795, 2173 salivary function 2179 salivary gland 1413 SAPHO syndrome 2269 scanning electron microscopy 875 scavenger receptor 1072 sciatica 170 SCID mice 1266 scintigraphy 1887 scleritis 413 scleroderma 561, 562, 563, 564, 565, 567, 569, 585, 587, 589, 591, 592, 594, 595, 598, 600, 601, 609, 612, 617, 622, 674, 675, 726, 727, 729, 1004, 1202, 1203, 1209, 1210, 1213, 1214, 1228, 1232, 1238, 1349, 1352, 1661, 1683, 1987, 1990, 1992, 1996, 2001, 2006, 2007, 2072, 2073, 2086, 2193, 2194, 2195, 2196, 2197, 2214, 2247 scn9a 96 score 1621 scoring methods 1954 SCOT trial (Scleroderma Cyclophosphamide or Transplant) 726 screening 1004, 1937, 1939 screening guideline adherence 1000 SDAI 73 seasonal variation 783 secular trend 685 segmental 1151 SELENA-SLEDAI 1456 self-directed program 691 self-efficacy 2280 self-management 689, 1334, 1408, 1562, 1745, 2062, 2282 self-reported arthritis 1460, 1462 semaphorins 361 semi-structured interview 1322 sensitive 118 sensitivity 522 sensitivity and specificity 1775 septic arthritis 1638 sequential therapy 1792 seroconversion 699 serologic tests 911, 1764 serotonin receptor 799 serum complement 1149 serum glycosylation 1105 serum trough levels 1826 service delivery 776, 1553 severity 707, 1087, 1600, 1876, 2218 sex bias 1193 sex hormones 63, 361, 1257 sex-differences 684 sexual dysfunction 812 sexual functioning 2073 SF-36 1211, 1848 SF-6D 2207 sham acupuncture 941 shared care 2280 shared decision making 1024 shared epitope 255, 1035, 1071, 1076, 2114, 2215 Sharp score 1734 Sharp/van der Heijde 1368 shingles 421 shoewear 1331 short form McGill pain questionnaire 2247 shoulder disorders 177 shrinking lung syndrome 1176 sicca 1886 side effects 31 abstract KEYWORD INDEX 2010 Program Book 371
- Page 1 and 2:
program B O O K Pre-Conference Cour
- Page 3 and 4:
program B O O K ABOUT ACR/ARHP EDUC
- Page 5 and 6:
TABLE OF CONTENTS ACCREDITATION . .
- Page 7 and 8:
TABLE OF CONTENTS ACR/ARHP Poster S
- Page 9 and 10:
TABLE OF CONTENTS Systemic Sclerosi
- Page 11 and 12:
the written consent of the ACR is p
- Page 13 and 14:
Shuttle Bus Service See shuttle sig
- Page 15 and 16:
ACR Resource Center Hours: Sunday,
- Page 17 and 18:
ACR Hotels + Map Complimentary shut
- Page 19 and 20:
to the premier meeting in rheumatol
- Page 21 and 22:
ACR Clinical Research Conference c/
- Page 23 and 24:
4:20 PM Germinal Center Reactions A
- Page 25 and 26:
3:30 PM Live Demonstration: Ultraso
- Page 27 and 28:
Upon completion of this session, pa
- Page 29 and 30:
MONDAY, NOVEMBER 8, 2010 ACR/ARHP R
- Page 31 and 32:
B301 Dermatological Manifestations
- Page 33 and 34:
Session Overview: The innate immune
- Page 35 and 36:
Upon completion of this session, pa
- Page 37 and 38:
B308 Inflammatory Eye Disease P/C M
- Page 39 and 40:
and insufficiency • recall source
- Page 41 and 42:
Session Overview: The advent of bio
- Page 43 and 44:
2:45 pm 641. Major Improvements in
- Page 45 and 46:
5 University of Twente and Medisch
- Page 47 and 48:
ACR/ARHP Combined Abstract Session
- Page 49 and 50:
REF 25th Anniversary Celebration 2:
- Page 51 and 52:
5:45 PM 699. Defining Latent and/or
- Page 53 and 54:
Lilian H. D. van Tuyl 8 , Karin Bri
- Page 55 and 56:
ACR REF Special Sessions 4:30 - 6:0
- Page 57 and 58:
REF 5K Run/Walk 6:00 - 8:00 am See
- Page 59 and 60:
• discuss the principles of early
- Page 61 and 62:
ACR Medical Aspects of Rheumatic Di
- Page 63 and 64:
10:00 am 1349. Work as a Daily Chal
- Page 65 and 66:
ACR Plenary Session II: Discovery 2
- Page 67 and 68:
B210 B301 Pediatrics: Periodic Feve
- Page 69 and 70:
Session Overview: As a clinical edu
- Page 71 and 72:
Thomas J. Murphy Ballroom Giant Cel
- Page 73 and 74:
3:45 PM 1367. Serum Urate Levels in
- Page 75 and 76:
A411 Rheumatoid Arthritis - Human E
- Page 77 and 78:
2:45 PM 1405. Development of a Visi
- Page 79 and 80:
4:30 PM Anti-citrullinated Protein
- Page 81 and 82:
of Experimental Orthopedics, Univer
- Page 83 and 84:
5:30 PM 1438. Mortality/Morbidity i
- Page 85 and 86:
5:30 PM 1456. Belimumab, a BLyS-Spe
- Page 87 and 88:
Develly 5 , Bernardo L. F. Fernande
- Page 89 and 90:
7:30 PM Role of IL-1 in Human Artic
- Page 91 and 92:
• compare the prevalence and epid
- Page 93 and 94:
6:45 PM Macrophage Activation Syndr
- Page 95 and 96:
Upon completion of this session, pa
- Page 97 and 98:
Session Overview: This roundtable d
- Page 99 and 100:
B303 Scleroderma: Systemic Sclerosi
- Page 101 and 102:
9:00 - 10:30 am - Poster Hall Morni
- Page 103 and 104:
• describe the role of IL-1 and I
- Page 105 and 106:
Session Overview: For the clinician
- Page 107 and 108:
• identify the aspects for day-to
- Page 109 and 110:
ACR Study Groups 1:00 - 2:00 PM B30
- Page 111 and 112:
Session Overview: Ultrasound and ma
- Page 113 and 114:
Session Overview: Fifty percent of
- Page 115 and 116:
1:20 PM Academic Rheumatology Seth
- Page 117 and 118:
ACR Concurrent Abstract Sessions 2:
- Page 119 and 120:
3:00 PM 2110. Rheumatologists on th
- Page 121 and 122:
2:45 PM 2133. Reasons for Decline i
- Page 123 and 124:
Session Overview: We are witnessing
- Page 125 and 126:
Session Overview: Systemic sclerosi
- Page 127 and 128:
Oaks, CA, 2 Amgen Inc., San Francis
- Page 129 and 130:
5:00 PM 2176. A Role of Autoimmune
- Page 131 and 132:
4:30 PM 2198. Association between V
- Page 133 and 134:
ARHP Concurrent Sessions 4:30 - 6:0
- Page 135 and 136:
THURSDAY, NOVEMBER 11, 2010 ACR/ARH
- Page 137 and 138:
• apply these basic statistics to
- Page 139 and 140:
9:15 AM The ACR/EULAR Definition of
- Page 141 and 142:
Immunology, Oslo University Hospita
- Page 143 and 144:
9:15 AM 2239. Factors Associated wi
- Page 145 and 146:
Upon completion of this session, pa
- Page 147 and 148:
Mikkel Østergaard 6 , Paul Emery 4
- Page 149 and 150:
Ende 4 , 1 Department of Rheumatolo
- Page 151 and 152:
ACR Poster Session A Cytokines, Med
- Page 153 and 154:
ACR Poster Session A 51. Associatio
- Page 155 and 156:
ACR Poster Session A 83. Respirator
- Page 157 and 158:
ACR Poster Session A 121. Bone Dens
- Page 159 and 160:
ACR Poster Session A 142. The Intra
- Page 161 and 162:
ACR Poster Session A 171. Early Pro
- Page 163 and 164:
ACR Poster Session A Pediatric Rheu
- Page 165 and 166:
ACR Poster Session A 233. Prevalenc
- Page 167 and 168:
ACR Poster Session A 266. Subtype S
- Page 169 and 170:
ACR Poster Session A 297. Body Weig
- Page 171 and 172:
ACR Poster Session A 325. Patient R
- Page 173 and 174:
ACR Poster Session A 356. Influence
- Page 175 and 176:
ACR Poster Session A 383. Efficacy
- Page 177 and 178:
ACR Poster Session A 409. Rituximab
- Page 179 and 180:
ACR Poster Session A 441. Recombina
- Page 181 and 182:
ACR Poster Session A 465. Immunoglo
- Page 183 and 184:
ACR Poster Session A 496. IRF8 Alle
- Page 185 and 186:
ACR Poster Session A 521. DC-STAMP
- Page 187 and 188:
ACR Poster Session A 546. Prevalenc
- Page 189 and 190:
ACR Poster Session A 571. Epidemiol
- Page 191 and 192:
ACR Poster Session A 599. Validatio
- Page 193 and 194:
ACR/ARHP Poster Session B Halls B1
- Page 195 and 196:
ACR Poster Session B 767. Economic
- Page 197 and 198:
ACR/ARHP Poster Session B 792. The
- Page 199 and 200:
ACR/ARHP Poster Session B Universit
- Page 201 and 202:
ACR/ARHP Poster Session B 848. Cell
- Page 203 and 204:
ACR/ARHP Poster Session B 886. Scre
- Page 205 and 206:
ACR/ARHP Poster Session B 909. Regu
- Page 207 and 208:
ACR/ARHP Poster Session B 935. The
- Page 209 and 210:
ACR/ARHP Poster Session B 967. Frac
- Page 211 and 212:
ACR Poster Session B 993. Early Exp
- Page 213 and 214:
ACR/ARHP Poster Session B 1022. Com
- Page 215 and 216:
ACR/ARHP Poster Session B 1055. Son
- Page 217 and 218:
ACR Poster Session B 1084. Gene Exp
- Page 219 and 220:
ACR/ARHP Poster Session B 1111. Inc
- Page 221 and 222:
ACR Poster Session B hiroshima Memo
- Page 223 and 224:
ACR/ARHP Poster Session B 1166. Pre
- Page 225 and 226:
ACR/ARHP Poster Session B 1199. Typ
- Page 227 and 228:
ACR/ARHP Poster Session B 1225. Phy
- Page 229 and 230:
ACR/ARHP Poster Session B 1262. Lat
- Page 231 and 232:
ACR/ARHP Poster Session B 1294. End
- Page 233 and 234:
ACR/ARHP Poster Session B 1321. Cha
- Page 235 and 236:
ACR/ARHP Poster Session C Halls B1
- Page 237 and 238:
ACR/ARHP Poster Session C 1495. S10
- Page 239 and 240:
ACR/ARHP Poster Session C 1524. Inc
- Page 241 and 242:
ACR/ARHP Poster Session C 1555. Pro
- Page 243 and 244:
ACR/ARHP Poster Session C 1583. Ass
- Page 245 and 246:
ACR/ARHP Poster Session C 1596. Gen
- Page 247 and 248:
ACR/ARHP Poster Session C 1622. Flu
- Page 249 and 250:
ACR/ARHP Poster Session C Miscellan
- Page 251 and 252:
ACR/ARHP Poster Session C L. Woodwa
- Page 253 and 254:
ACR/ARHP Poster Session C 1692. Res
- Page 255 and 256:
ACR/ARHP Poster Session C 1719. Los
- Page 257 and 258:
ACR/ARHP Poster Session C 1749. Con
- Page 259 and 260:
ACR/ARHP Poster Session C 1780. Tow
- Page 261 and 262:
ACR/ARHP Poster Session C 1804. Eff
- Page 263 and 264:
ACR/ARHP Poster Session C Immunolog
- Page 265 and 266:
ACR/ARHP Poster Session C 2 Departm
- Page 267 and 268:
ACR/ARHP Poster Session C CA, 29 Un
- Page 269 and 270:
ACR/ARHP Poster Session C 1900. IL-
- Page 271 and 272:
ACR/ARHP Poster Session C 1930. Cor
- Page 273 and 274:
ACR/ARHP Poster Session C 1958. The
- Page 275 and 276:
ACR/ARHP Poster Session C 1988. Cha
- Page 277 and 278:
ACR/ARHP Poster Session C 2015. CpG
- Page 279 and 280:
ACR/ARHP Poster Session C 2038. Pri
- Page 281 and 282:
ACR/ARHP Poster Session C 2070. Ass
- Page 283 and 284:
REF Industry Roundtable-supported S
- Page 285 and 286:
REF Industry Roundtable-supported S
- Page 287 and 288:
INDUSTRY-SUPPORTED POST-CONFERENCE
- Page 289 and 290:
2010 ACR/ARHP Annual Meeting Leader
- Page 291 and 292:
2010 ACR/ARHP Annual Meeting Leader
- Page 293 and 294:
FLOOR PLANS 2010 Program Book 291
- Page 295 and 296:
VISIT THE EXHIBIT HALL New and inno
- Page 297 and 298:
EXHIBITORS La Lettre Du Rhumatologu
- Page 299 and 300:
ACKNOWLEDGEMENTS The ACR, the ARHP
- Page 301 and 302:
ACR/ARHP/REF STAFF LISTING Administ
- Page 303 and 304:
A Ahmed, Rafi, PhD T cell Memory .
- Page 305 and 306:
Cooper, Max D, MD Introduction . .
- Page 307 and 308:
Gerlag, Danielle Marie, MD, PhD The
- Page 309 and 310:
Physical Examination Skills for Imp
- Page 311 and 312:
Meroni, Pierluigi, MD Autoantibodie
- Page 313 and 314:
Rogers, Joan C, PhD, OTR/ L Underst
- Page 315 and 316:
Terkeltaub, Robert, MD Crystallizin
- Page 317 and 318:
A Aarden, L 1825 Aarrass, S 1519, 1
- Page 319 and 320:
Bakker, AAB 1095 Barendregt, B 753
- Page 321 and 322: Boutin-Le Thi Huong, D 478 Bout-Tab
- Page 323 and 324: Chatham, WW 457, 1146, 1454, 1457,
- Page 325 and 326: Daudon, M 875 Daugas, E 2009 Davatc
- Page 327 and 328: Ehst, B 758 Eicher, JL 688 Eisen, S
- Page 329 and 330: Gabay, OH 1484 Gaber, T 630, 1418 G
- Page 331 and 332: Guan, M 965 Guañabens, N 975 Gudbj
- Page 333 and 334: Homme, CL 730 Honda, E 434 Hong, JY
- Page 335 and 336: Kambayashi, T 1354 Kamdar, AA 1160
- Page 337 and 338: Kuller, LH 71 Kumabe, M 1164 Kumaga
- Page 339 and 340: Looney, C 941 Looney, MR 609 Looney
- Page 341 and 342: McCarthy, GM 1109, 1306, 1426 McCau
- Page 343 and 344: Myouzen, K 1577 Mysiw, WJ 2096 Mysl
- Page 345 and 346: Pans, M 1834 Parra, ER 605, 887 Ped
- Page 347 and 348: Radka, S 1174 Radner, H 296, 1745 R
- Page 349 and 350: Sack, KE 1898 Sacli, SF 1312 Saddic
- Page 351 and 352: 1463, 2071, 2140, 2141 Singh, K 212
- Page 353 and 354: Takahata, M 1492 Takasaki, Y 1731 T
- Page 355 and 356: 636 van Dongen, CJJ 90 Van Doornum,
- Page 357 and 358: Witte, T 824, 1578, 1579, 2214 Witt
- Page 359 and 360: A α-galactosylceramide 505 A2A kno
- Page 361 and 362: Behcet’s syndrome 1284, 1288, 129
- Page 363 and 364: cost-utility 759, 1539 couples 1324
- Page 365 and 366: fibroblast like synoviocyte 27 fibr
- Page 367 and 368: impact 1063, 1325 inactive disease
- Page 369 and 370: methylation 826, 1253, 1489 methylt
- Page 371: 233, 234, 240, 243, 252, 262, 268,
- Page 375 and 376: 1226, 1227, 1229, 1230, 1231, 1233,
- Page 377 and 378: Abelson, Abby Goulder, MD Education
- Page 379 and 380: Massarotti, Elena M, MD Systemic Lu
- Page 381 and 382: ACR Annual Meeting fellowS-in-train
- Page 383 and 384: NOTES 2010 Program Book 381
- Page 385 and 386: Enbrel ® (etanercept) Brief Summar
- Page 387 and 388: Prescription Enbrel ® (etanercept)
Change language